Anixa Biosciences (ANIX) Cash & Equivalents (2010 - 2026)
Anixa Biosciences (ANIX) recorded Cash & Equivalents of $1.4 million in fiscal Q3 2026 (quarter ended Jul 31, 2026), down 6.5% from $1.5 million a year earlier and down 5.3% from the prior quarter.
Powered by 
Analysis
Anixa Biosciences (ANIX) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025 (ended Oct 31, 2025), Anixa Biosciences reported Cash & Equivalents of $1.24 million, down 2.1% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of -28.0% (FY2020 to FY2025).
- Across earlier fiscal years, Cash & Equivalents came in at $1.27 million in FY2024 (+38.9%), $915,000 in FY2023 (-92.6%), $12.36 million in FY2022 (-57.6%) and $29.13 million in FY2021 (+353.9%).
- Quarterly Cash & Equivalents has ranged from $915,000 in fiscal Q4 2023 to $29.78 million in fiscal Q1 2022 over the past five years.
- On a year-over-year basis, Cash & Equivalents rose in four of the last seven quarters, with growth averaging 18.2%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 353.9% in fiscal Q4 2021, against a decline of 92.6% in fiscal Q4 2023 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Anixa Biosciences | 102.02 Mn | 100.75 Mn | - | 1.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 1.40 Mn |
| Apr 30, 2026 | 1.48 Mn |
| Oct 31, 2025 | 1.24 Mn |
| Jul 31, 2025 | 1.50 Mn |
| Apr 30, 2025 | 1.91 Mn |
| Jan 31, 2025 | 1.05 Mn |
| Oct 31, 2024 | 1.27 Mn |
| Jul 31, 2024 | 1.23 Mn |
| Apr 30, 2024 | 995,000.00 |
| Jan 31, 2024 | 998,000.00 |
| Oct 31, 2023 | 915,000.00 |
| Jul 31, 2023 | 3.20 Mn |
| Apr 30, 2023 | 5.62 Mn |
| Jan 31, 2023 | 9.79 Mn |
| Oct 31, 2022 | 12.36 Mn |
| Jul 31, 2022 | 24.25 Mn |
| Apr 30, 2022 | 27.73 Mn |
| Jan 31, 2022 | 29.78 Mn |
| Oct 31, 2021 | 29.13 Mn |
| Jul 31, 2021 | 27.22 Mn |
API Access
Anixa Biosciences Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ANIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ANIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ANIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();